pDONR223-CLK2 Citations (1)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-CLK2
| Articles |
|---|
| Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression. Van Goubergen J, Perina M, Handle F, Morales E, Kremer A, Schmidt O, Kristiansen G, Cronauer MV, Santer FR. Mol Oncol. 2025 Feb;19(2):496-518. doi: 10.1002/1878-0261.13728. Epub 2024 Sep 11. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.